^
Association details:
| Biomarker: | TOP2A amplification |
|---|---|
| Cancer: | Rectal Cancer |
| Drug: | daunorubicin (Topoisomerase II inhibitor, DNA intercalator) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Drug Repositioning Based on the Reversal of Gene Expression Signatures Identifies TOP2A as a Therapeutic Target for Rectal Cancer
Published date:
10/31/2022
Excerpt:
Significantly, gains of TOP2A inversely correlated with the sensitivity of doxorubicin, daunorubicin, idarubicin, epirubicin, teniposide, and mitoxantrone (Figure 4c). Moreover, the expression levels of TOP2A inversely correlated with the sensitivity of daunorubicin, idarubicin, epirubicin, teniposide, and mitoxantrone (Figure 4c)....These findings can be translated into clinical practice to evaluate TOP2A status for targeted and personalized therapies based on topoisomerase II inhibitors in rectal cancer patients.
DOI:
10.3390/cancers13215492
